Joel Kaye
机构: Pharmacology Project Leader, Teva Pharmaceutical Industries Ltd
每年引用次数
引用次数
引用: 1,548
H-指数: 20
I10-指数 : 26
出版物: 100
Anti-clusterin monotherapy for cancer treatment
Shoshi Tessler , Tania Fine , Joel Kaye , Rina Kashi
2014
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
Nora Tarcic , Joel Kaye , Eran Blaugrund
14
2011
Treatment of ocular inflammatory diseases using laquinimod
Nora Tarcic , Hussein Hallak , Joel Kaye
4
2013
A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.
Kees Smid , Chang-Ho Ahn , Godefridus J Peters , Tania Fine
Anticancer Research 34 ( 12) 6951 -6959
15
2014
Laquinimod targets the aryl hydrocarbon receptor (AhR) pathway in periphery and brains of naïve and EAE mice (P2.365)
Iris Grossman , Brian Weiner , Joel Kaye , Ralph Laufer
Neurology 88
2017
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
Jessica E. Kenison , Francisco J. Quintana , Kalil Alves de Lima , Maisa C. Takenaka
Neuroimmunology and Neuroinflammation 8 ( 2)
2
2021
Laquinimod ameliorates secondary brain inflammation.
Julia Nedelcu , Christin Reinbach , Philipp Riedler , Matthias Brendel
Neurobiology of Disease 134 104675 -104675
4
2020
2,3,7,8-Tetrachlorodibenzo-p-dioxin Induces Vascular Dysfunction That is Dependent on Perivascular Adipose and Cytochrome P4501A1 Expression.
Mary T. Walsh-Wilcox , Joel Kaye , Efrat Rubinstein , Mary K. Walker
Cardiovascular Toxicology 19 ( 6) 565 -574
1
2019
Cognitive disturbances in the cuprizone model of multiple sclerosis.
Maksym V. Kopanitsa , Kimmo K. Lehtimäki , Markku Forsman , Ari Suhonen
Genes, Brain and Behavior 20 ( 1)
2021
Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.
Stefanie Kuerten , Leila J. Jackson , Joel Kaye , Timothy L. Vollmer
CNS Drugs 32 ( 11) 1039 -1051
13
2018
Laquinimod Supports Remyelination in Non-Supportive Environments.
Stella Nyamoya , Julia Steinle , Uta Chrzanowski , Joel Kaye
Cells 8 ( 11) 1363
7
2019
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Joel Kaye , Victor Piryatinsky , Tal Birnberg , Tal Hingaly
Proceedings of the National Academy of Sciences of the United States of America 113 ( 41) 201607843
65
2016
Directed evolution of a soluble human IL-17A receptor for the inhibition of psoriasis plaque formation in a mouse model.
Marianna Zaretsky , Revital Etzyoni , Joel Kaye , Liora Sklair-Tavron
Chemistry & Biology 20 ( 2) 202 -211
17
2013
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.
Nicole Kerlero de Rosbo , Michael Hoffman , Itzhack Mendel , Israel Yust
European Journal of Immunology 27 ( 11) 3059 -3069
168
1997
Laquinimod modulates central nervous system inflammation via the aryl hydrocarbon receptor and is effective in the chronic NOD progressive EAE model (P2. 353)
Joel Kaye , Ralph Laufer , Jessica Kenison , Veit Rothhammer
Neurology 88 ( 16 Supplement)
2017
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling
Renata Ferrarotto , Vasudha Mishra , Elad Herz , Adar Yaacov
Cell Death & Disease 13 ( 8) 678 -678
22
2022
Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation
Laura Feeney , Brindley Hapuarachi , Helen Adderley , Sam Rack
Oral Oncology 133 106028 -106028
19
2022
Bisfluoroalkyl-1, 4-benzodiazepinone compounds for treating desmoid tumors
Bruce S Fischer , Gaurav Bajaj , Matti Davis , Joel Kaye
2023
Treatment of Crohn's disease with laquinimod
Nora Tarcic , Asi Haviv , Eran Blaugrund , Joel Kaye
105
2013
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
Joel Kaye , Eran Blaugrund , Nora Tarcic
22
2013